Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alisporivir
- Development stage
- Phase 3
- Lead developer
- Debiopharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alisporivir is a non-immunosuppressive, second-generation cyclophilin inhibitor structurally related to cyclosporin A. It acts by inhibiting the host protein cyclophilin A, thereby blocking its peptidyl-prolyl isomerase activity, which is essential for the replication of certain viruses such as hepatitis C virus (HCV). Unlike cyclosporin A, alisporivir does not suppress the immune system. The drug has demonstrated broad-spectrum antiviral activity and has been evaluated in clinical trials for hepatitis C and chronic hepatitis C. Additional research has explored its potential use in Duchenne muscular dystrophy, Alzheimer's disease, other viral infections (such as tick-borne encephalitis), and myocardial infarction. Alisporivir is being developed by Debiopharm (Japan) and Novartis (rest of world)[1][3][4][5][8].
- Other names
- alisporivir
02
Targets
PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on alisporivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alisporivir.